LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
16
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In DXC Technology Company To Contact The Firm

NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in DXC Technology Company ("DXC" or the "Company")(NYSE: DXC ) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in DXC stock or options between February 8, 2018 and November 6, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/DXC. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Virginia on behalf of all those who purchased DXC common stock between February 8, 2018 and November 6, 2018 (the "Class Period"). The case, City of Warren Police and Fire Retirement System v. DXC Technology Company et al. , No. 18-cv-01599 was filed on December 27, 2018, and has been assigned to Judge Anthony John Trenga.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) the Company had changed or planned to change the operations of its sales teams; (2) the Company was deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (3) that the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby losing sales and revenue opportunities; and (4) that, as a consequence, the Company’s revenue and financial performance guidance for fiscal 2019 was without a reasonable basis.

On November 6, 2018, the Company reported its second quarter FY19 financial results. On the same day, during a conference call for investors, the Company also disclosed that it had indeed lost big sales to significant customers, that quarterly revenues would fall short of expectations by hundreds of millions of dollars, and that the Company would reduce its FY19 revenue outlook by $800 million.

On this news, DXC's share price fell from $71.99 per share on November 6, 2018 to a closing price of $63.02 on November 7, 2018: a $8.97 or a 12.46% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding DXC's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 7

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 4

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading

Top 5 Most Recently Viewed Articles

BioVaxys Unveils Private Placement to Boost Growth Initiatives

Updated Category News Views 83

BioVaxys Technology Corp. Announces Private Placement Offering BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) is thrilled to share its plans for a strategic move that aims to elevate its operational capabilities. The company intends to initiate a non-brokered private placement offering, introducing up to 14,285,715 units at a price of CAD$0.07 each. This initiative is...

Continue Reading
Cardiff Oncology Secures $40 Million Through Oversubscribed Offering

Updated Category News Views 104

Cardiff Oncology Completes Significant Stock Offering Cardiff Oncology, Inc. (Nasdaq: CRDF) has recently made headlines with its successful pricing of an underwritten offering, targeting a remarkable $40 million. This offering consists of 15,384,619 shares of its common stock, priced at $2.60 per share, with all shares being offered by the Company itself. The...

Continue Reading
Sungrow and Globeleq Partner for Major Battery Storage Project

Updated Category News Views 301

Sungrow and Globeleq Join Forces on Groundbreaking Energy Project Sungrow, a prominent name in the renewable energy sector, and Globeleq, a trusted independent power producer, have made a significant commitment by signing a term sheet. This partnership focuses on the supply and long-term service for the ambitious 153MW / 612MWh Red Sands Battery Energy Storage System...

Continue Reading
Helios Technologies Unveils the Advanced S35 Display System

Updated Category News Views 442

Helios Technologies Launches the Versatile S35 Display Helios Technologies, Inc. (NYSE: HLIO), known for its expertise in highly engineered motion control and electronic controls technology, has recently introduced the S35 display. This new addition showcases a unique blend of advanced technology, rugged durability, and user-friendliness, making it an exceptional...

Continue Reading
Ameriprise Financial Soars to New Heights: Stock Insights

Updated Category News Views 47

Ameriprise Financial Achieves All-Time High Ameriprise Financial Inc (NYSE: AMP) has recently marked an extraordinary achievement with its stock price reaching an all-time high of $524.01. This significant increase not only highlights the company’s performance but also reflects a robust surge in investor confidence, demonstrated by a remarkable 65.08% increase over the...

Continue Reading